文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

德国全国代表性队列中脂蛋白(a)与心血管和脑血管疾病的关联

Association of Lipoprotein(a) With Cardiovascular and Cerebrovascular Disease in a Nationally Representative Cohort of Germany.

作者信息

Gelfert Gloria G, Grittner Ulrike, Kuhnert Ronny, Scheidt-Nave Christa, Endres Matthias, Nave Alexander H

机构信息

Center for Stroke Research Berlin (CSB), Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Department of Neurology with Experimental Neurology, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.

Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH) at Charité, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.

出版信息

JACC Adv. 2025 Jul 23;4(8):102015. doi: 10.1016/j.jacadv.2025.102015.


DOI:10.1016/j.jacadv.2025.102015
PMID:40706144
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12309279/
Abstract

BACKGROUND: Population-based data on the distribution of lipoprotein(a) (Lp[a]) within the German population are lacking. OBJECTIVES: The aim of the study was to determine the age- and sex-specific Lp(a) distribution in Germany and analyze its association with different types of cardiovascular disease (CVD). METHODS: We analyzed cross-sectional data from the German National Health Interview and Examination Survey 1998, a population-based study representing the German adult population's health status from 1997 to 1999. We examined serum Lp(a) according to demographics and investigated associations between Lp(a) and history of self-reported CVD. We tested Lp(a) in spline analysis on continuous scales and as dichotomous Lp(a) thresholds. RESULTS: In the German National Health Interview and Examination Survey 1998 (n = 6,657), median Lp(a) was 15.3 mg/dL (Q1-Q3: 5.6, 43.1). Lp(a) levels ≥50 mg/dL were present in 21.6%. Men had substantially higher median Lp(a) than women (22.1 mg/dL vs 10.3 mg/dL). Median Lp(a) levels were significantly higher in individuals with than without a history of atherosclerotic cardiovascular disease (ASCVD) but did not significantly differ between people with and without venous thrombosis. In logistic regression analysis with splines, higher Lp(a) levels were associated with a higher probability of a history of CVD. In logistic regression analyses, Lp(a) ≥50 mg/dL was associated with a history of ASCVD (OR: 1.36 [95% CI: 1.04-1.78]; P = 0.023). CONCLUSIONS: About 1 in 5 German individuals from a prestatin era population had Lp(a) levels ≥50 mg/dL. Higher levels were independently associated with ASCVD, but not with venous thrombosis. These findings provide a basis for future prospective studies to define the role of Lp(a) in CVD risk in the German population.

摘要

背景:德国人群中脂蛋白(a) [Lp(a)]分布的基于人群的数据尚缺。 目的:本研究旨在确定德国Lp(a)的年龄和性别特异性分布,并分析其与不同类型心血管疾病(CVD)的关联。 方法:我们分析了1998年德国国民健康访谈与检查调查的横断面数据,这是一项基于人群的研究,代表了1997年至1999年德国成年人群的健康状况。我们根据人口统计学特征检查血清Lp(a),并调查Lp(a)与自我报告的CVD病史之间的关联。我们在连续量表的样条分析中以及作为二分Lp(a)阈值来检测Lp(a)。 结果:在1998年德国国民健康访谈与检查调查(n = 6657)中,Lp(a)中位数为15.3 mg/dL(四分位数间距:5.6,43.1)。Lp(a)水平≥50 mg/dL的占21.6%。男性的Lp(a)中位数显著高于女性(22.1 mg/dL对10.3 mg/dL)。有动脉粥样硬化性心血管疾病(ASCVD)病史的个体的Lp(a)中位数水平显著高于无此病史者,但有和无静脉血栓形成者之间无显著差异。在样条逻辑回归分析中,较高的Lp(a)水平与CVD病史的较高概率相关。在逻辑回归分析中,Lp(a)≥50 mg/dL与ASCVD病史相关(比值比:1.36 [95%置信区间:1.04 - 1.78];P = 0.023)。 结论:在他汀类药物使用前时代的德国人群中,约五分之一的个体Lp(a)水平≥50 mg/dL。较高水平与ASCVD独立相关,但与静脉血栓形成无关。这些发现为未来前瞻性研究确定Lp(a)在德国人群CVD风险中的作用提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/7beb9668ef5e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/ca34eff80ac4/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/ca34eff80ac4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/98b90791bd80/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/b4c77b1f6230/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/7beb9668ef5e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/ca34eff80ac4/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/ca34eff80ac4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/98b90791bd80/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/b4c77b1f6230/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8c/12309279/7beb9668ef5e/gr3.jpg

相似文献

[1]
Association of Lipoprotein(a) With Cardiovascular and Cerebrovascular Disease in a Nationally Representative Cohort of Germany.

JACC Adv. 2025-7-23

[2]
Intra-individual Variability in Lipoprotein(a) Levels: Findings from a Large Academic Health System Population.

Eur J Prev Cardiol. 2024-10-24

[3]
Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study.

Eur J Prev Cardiol. 2025-7-14

[4]
Assessment of the Utilization of Lipoprotein (a) and its Relationship with Cardiovascular Outcomes: A Retrospective Cohort Study from a Public Hospital in New York City.

Heart Views. 2025

[5]
Traditional Risk Factors, Optimal Cardiovascular Health, and Elevated Lipoprotein(a).

Eur J Prev Cardiol. 2024-11-28

[6]
Lipoprotein(a) as an early marker of cardiovascular events in high-risk subjects: insights from the Moli-sani cohort study.

Front Cardiovasc Med. 2025-7-8

[7]
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.

Circulation. 2025-1-28

[8]
AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank.

JAMA Cardiol. 2025-6-4

[9]
Sertindole for schizophrenia.

Cochrane Database Syst Rev. 2005-7-20

[10]
Prescription of Controlled Substances: Benefits and Risks

2025-1

本文引用的文献

[1]
Testing practices and clinical management of lipoprotein(a) levels: A 5-year retrospective analysis from the Johns Hopkins Hospital.

Am J Prev Cardiol. 2024-6-19

[2]
Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank.

Atherosclerosis. 2024-2

[3]
Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses.

Atherosclerosis. 2023-2

[4]
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.

Open Heart. 2022-10

[5]
Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees.

Curr Opin Lipidol. 2022-12-1

[6]
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022-10-14

[7]
Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study.

Atherosclerosis. 2022-8

[8]
Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.

Atherosclerosis. 2022-5

[9]
Lipoprotein(a), Menopausal Hormone Therapy, and Risk of Coronary Heart Disease in Postmenopausal Individuals.

JAMA Cardiol. 2022-5-1

[10]
Lipoprotein(a) and Metabolic Syndrome.

Dtsch Arztebl Int. 2022-4-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索